Many anti-cancer drugs induce formation of lipid peroxidation products that are toxic for lung cancer cells in vitro. We tested whether changes of serum thiobarbituric acid reactive substances (TBARs) and Schiff's bases (SB) are associated with treatment efficacy in 37 small cell lung cancer (SCLC) patients. Subjects received carboplatin (350 mg/m 2 , i.v.-Day 1), vincristine (1.3 mg/m 2 , i.v.-Day 1), and etoposide (120 mg/m 2 , oral dose-Days 1-4). Then 5 subsequent cycles were repeated at 21-day intervals. Serum TBARs and SB were measured fluorimetrically before and 6, 24 h after introduction of the 1st, 3rd and 6th cycles.
Introduction
Patients with lung cancer have increased concentration of lipid peroxidation products in body fluids that may result from systemic oxidative stress. Plasma levels of malondialdehyde (MDA), a one of the most important end-products of lipid peroxidation were higher in lung cancer patients than in healthy matched controls. 1, 2 Pleural exudates obtained from these patients revealed higher concentration of lipid peroxidation products and decreased antioxidant defense than specimens from subjects with non-malignant pulmonary diseases. 3 In addition, the content of end-products of lipid peroxidation including MDA and spontaneous H 2 O 2 generation were higher in lung cancer tissue than in matched-uninvolved lung parenchyma. 4, 5 Recently, MDA has been shown to induce cell cycle arrest in a cell line derived from human large cell lung carcinoma in vitro. 6 Other lipid peroxidation products generated from eicosapentaenoic acid and docosahexaenoic acid were also able to inhibit growth of lung adenocarcinoma cell cultures. 7 Moreover, strong immunoreactivity of primary lesions and metastatic lymph nodes for glutathione peroxidase and superoxide dismutase, enzymes that suppress lipid peroxidation, was related to poor prognosis in patients with lung adenocarcinoma. 8 These suggest that elevated lipid peroxidation may represent some kind of metabolic adaptation favouring formation of products that may inhibit lung cancer growth.
Many anticancer drugs are known to induce free radical generation and cause peroxidative damage to lipids and other biomolecules. 2, [9] [10] [11] [12] The rise in concentration of circulating lipid peroxidation products was observed in patients with different carcinomas as a consequence of various chemotherapy regimens. 2, 11 This could be responsible in part for their neoplastic activity and also for the development of side effects such as cardiomyopathy, nephrotoxicity and lung fibrosis. 9, 13, 14 To date, there is no information available regarding association between chemotherapy-induced alterations in serum levels of lipid peroxidation products and treatment efficacy in cancer patients. Therefore, in this study we investigated changes of serum concentrations of lipid peroxidation products, thiobarbituric acid reactive substances (TBARs), and Schiff's bases (SB) after the 1st, 3rd and 6th courses of chemotherapy regimen composed of carboplatin, vincristin and etoposide in patients with small cell lung cancer (SCLC) with respect to the treatment efficacy.
We describe herein the rise in serum TBARs and SB concentrations after introduction of the 1st course of chemotherapy that correlated with SCLC patients survival. Non-responders with early occurrence of progressive disease and shortest survival revealed the 1st cycle-induced decrease in circulatory lipid peroxidation products.
Material and methods

Patients
Thirty-seven patients (mean age 56710 years, 12 women, 28 men) with previously untreated, histologically or cytologically confirmed SCLC admitted to District Chest Hospital Lagiewniki were recruited for the study from March 1997 to August 1998. All patients were required to have Karnofsky performance status X60, adequate hematological (white blood cell count44 Â 10 3 =ml, platelet count410 5 =ml), renal (serum creatinine level o1:5 mg=dl) and hepatobiliary (serum bilirubin level o1:5 mg=dl) function. Pretreatment evaluation consisted of a complete history and physical examination, chest X-ray, bronchofibroscopy, computerized tomographic scans of the chest, ultrasonography of abdomen, blood cell count and serum chemistry analysis. Computerized tomographic scans of the central nervous system and radionuclide bone scans were performed when brain and bone metastases were suspected. Twenty patients revealed limited stage (LD) and 17 extensive stage disease (ED) ( Table 1 ). Sites of metastases were liver-9 patients, bone-6 patients, and central nervous system-2 patients. Blood cell count and serum chemistry analysis were repeated prior to each cycle of chemotherapy. Radiographic studies were reassessed following every cycle or as indicated by clinical situation. All subjects were smokers and did not change smoking habits during the study. No patient had any concomitant inflammatory disease during the study period. The study had the approval of the Ethics Committee of Medical University of Lodz, and informed consent was obtained.
Treatment regimen and blood collection
The treatment regimen consisted of carboplatin and etoposide (Bristol-Myers Squibb, Syracuse, NY) and vincristine (Richter, Hungary). Carboplatin (350 mg/m 2 , i.v. infusion in 500 ml of 0.9% saline lasting 2 h), vincristine (1.3 mg/m 2 , i.v. bolus, no more than 2 mg a day) and etoposide (120 mg/m 2 , single oral dose) were administered at the 1st day. The administration of etoposide was continued for the next 3 consecutive days. Following the initial 4-day cycle, 5 subsequent cycles were repeated at 21 day intervals. Additional treatment involved antiemetic drugs, and oral corticosteroids if required. Blood specimens for determination of lipid peroxidation products-TBARs, SB, were drawn just before and 6, 24 h after introduction of the 1st, 3rd and 6th courses of chemotherapy. Clotted blood (30 min incubation at 37 1C) was centrifuged and obtained serum was stored at À80 1C for not longer than 14 days.
Response and toxicity criteria
Monthly evaluation of response to chemotherapy involved clinical examination, assessment of the chest X-ray, liver function tests, abdomen ultrasonography, computerized tomographic scans and other imaging studies as clinically indicated. Tumour response before the 3rd and 6th courses of chemotherapy was evaluated by standard WHO criteria. A complete response (CR) was defined as resolution of all disease for a minimum of 4 weeks. A partial response (PR) required a 50% or greater decrease in the tumor size (the sum of the products of measured lesions) for a minimum of 4 weeks without the appearance of new lesions. Stable disease (NC) was defined as a response less than a partial response or progression less than that defined as progressive disease, of at least four week duration. Progressive disease (PD) was described as a greater than 25% enlargement of an indicator lesion or development of a new lesion. Patients were classified as responders (complete response þ partial response) and non responders (stable disease þ progressive disease).The therapy was discontinued in patients with progressive disease. Patients who had a white blood cell counto3 Â 10 3 =ml or plateletso10 4 =ml on the day of scheduled treatment had drug administration delayed by 1 week (maximum 2 weeks) until the counts rose above these levels. Since colony stimulating factors may prime phagocytes to enhanced ROS production with subsequent rise in circulating lipid peroxidation products they were not used during this study. From the same reasons the radiation therapy was omitted in SCLC LD patients.
Lipid peroxidation products
Quantitative estimation of lipid peroxidation included assays for TBARs and SB. 15, 16 TBARs-0.1 ml of serum was mixed with 1 ml of 0.05 M sulphuric acid and 0.5 ml of 1.23 M trichloroacetic acid and incubated for 5 min at room temperature. Then the sample was centrifuged (1500g, 10 min, 4 1C) and the pellet was suspended in 2 ml of distilled water acidified with HCl to pH ¼ 2:5 and then 0.5 ml 0.025 M thiobarbituric acid solution and 10 ml 0.01% butylated hydroxytoluene was added. After vigorous shaking the sample was boiled for 60 min, mixed with 2.5 ml of n-butanol and again centrifuged (1500g, 10 min, room temperature). TBARs were measured fluorometrically (excitation 515 nm, emission 546 nm) in the upper (butanol) layer on a Perkin Elmer Luminescence Spectrometer LS 50 B. Tetramethoxypropane (0.1-15 mmol/dl) was used as an external standard and TBARs concentration was expressed in mmol/dl. SB-70 ml of serum was mixed with 980 ml of chloroform-methanol mixture (2:1, v/v), adjusted to pH 2.3 with HCl and then vigorously shaken and centrifuged (1500g, 10 min, 20 1C). SB were determined fluorometrically (excitation 360 nm, emission 430 nm) in supernatant and results were expressed in arbitrary units of fluorescence per 1 ml of serum (U 430 /ml).
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Other techniques
Blood cell count was performed with ABX MICROS analyser (AVL, Montpellier France). Serum levels of transferrin (nephelometric assay, Beckman Array 360 system) and iron were done by Diagnostic Laboratory of Academic Teaching Hospital of Medical University of Lodz.
Statistical analysis
Data are expressed as mean 7SD (and median in the case of patients survival). The effect of chemotherapy cycles on serum TBARs and SB concentrations was analyzed using Wilcoxon matched pairs tests followed Friedman ANOVA test. The differences between patients subgroups were computed with Mann-Whitney U-test or Friedman ANOVA test. Correlation coefficients were calculated by the Spearman test. The log-rank test and the Kaplan-Meier method were used for analysis of survival from the treatment introduction. A P value o0:05 was considered significant.
Results
Treatment results
Nineteen patients with SCLC (11 with LD and 8 with ED) completed 6 courses of chemotherapy. They had the complete or partial response (subgroup of responders ) that was maintained at least up to the end of treatment. Of them, two patients were alive at the moment of study completion (survival 41360 and 41764 days). For the remaining 17 responders the survival ranged from 125 to 869 days (median ¼ 311 days). Eighteen patients (9 with LD and 9 with ED) did not respond to the chemotherapy (non-responders, survival range 5-322 days, median 67 days). In 9 patients (1 with LD and 8 with ED) the progressive disease occurred before the 2nd chemotherapy cycle (early progression, survival from 5 to 65 days, median 22 days) and in the other 9 patients (8 with LD and 1 with ED) progressive disease was observed between the 3rd and 6th courses (late progression, survival 69 days till 322 days, median 136 days). These subjects were withdrawn from the chemotherapy regimen, however, they received palliative treatment (including radiotherapy and other anticancer drugs) as needed. Also, patients who completed 6 courses of chemotherapy received further anticancer treatment according to indications. Fig. 1C shows individual patients survival results ranging from 5 till 869 days (median ¼ 151 days). Figure 1 (A and B) shows individual increments in lipid peroxidation products after 24 h from introduction of the 1st chemotherapy cycle. The TBARs increment expressed as % of baseline (before the 1st chemotherapy cycle) value was negative in 8 patients and positive in 29 patients and ranged from -62% to +737% (Fig. 1A) . Serum SB increment ranged from À56.1% to +151.3% and was negative in 9 subjects. There was a significant correlation between TBARs and SB increments (r ¼ 0:63, Po0:0001), as well as between baseline SB and TBARs (r ¼ 0:53, Po0:001). In 28 patients, serum TBARs and SB levels raised in response to chemotherapy, in 8 subjects both variables decreased and in one patient the increase in TBARs and decrease in SB after treatment introduction was observed ( Fig. 1A and B ). Baseline concentration of TBARs and SB was higher in SCLC ED patients than in SCLC LD subjects, 3.5270.31 mmol/dl vs. 1.7870.19 mmol/dl (Po0:0001) and 37.37 4.5 U 430 /ml vs. 17.071.5 U 430 /ml, (Po0:001), respectively. The 1st cycle of chemotherapy induced the significant rise in circulatory TBARs and SB in the whole group of SCLC patients and also in the subgroup of responders. The mean TBARs and SB concentration increased by 1.61 and 1.13 times 24 h after the 1st chemotherapy course introduction in the whole SCLC group (Table 2) . On the contrary, in non-responders no rise and even significant decrease in end-products of lipid peroxidation (TBARs at 6 and 24 h) was observed. Prospective analysis revealed that the 1st cycle of chemotherapy did not increase serum TBARs and SB levels only in SCLC ED non-responders ( Table 3) .
Effect of the 1st chemotherapy course on serum lipid peroxidation products
The increase in circulatory end-products of lipid peroxidation was observed in all remaining subgroups with the highest rise in TBARs (2.78-fold) and SB (1.62-fold) in SCLC LD responders. The effect of the 1st chemotherapy course on serum end-products of lipid peroxidation was quite different in non-responders with early and late progression. In non-responders with the late progression, both TBARs and SB increased significantly 24 h after the 1st cycle introduction while in subjects with early progression the decline was observed ( Table 4 ). SCLC patients with early progression had higher baseline (before the 1st chemotherapy cycle) TBARs and SB concentrations than those with the late progression.
Effect of consecutive chemotherapy cycles on serum end-products of lipid peroxidation
Monitoring of circulatory products of lipid peroxidation in 19 SCLC responders showed significant increase in TBARs (Po0:0001) and SB (Po0:02) levels in blood samples taken just before consecutive courses of chemotherapy ( Fig. 2A and B) . The baseline TBARs and SB concentration before the 6th course was 1.44 (Po0:01) and 1.21 times (Po0:01) higher than that before the 1st one, respectively. On the other hand, the mean increments in serum concentrations of TBARs and SB caused by chemotherapy were highest for the 1st course and decreased gradually (Po0:02 and 0.001) with treatment duration (Fig. 2C and D) . For instance, mean TBARs increment was 1.68 times lower after the 6th chemotherapy course than after the 1st one (Po0:01). 
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Patients survival and changes of lipid peroxidation products after the 1st course of chemotherapy
There was a positive correlation between the 1st chemotherapy cycle-induced increment in circulatory TBARs and SB and patients survival; r ¼ 0:49, Po0:001 and r ¼ 0:56, Po0:002, respectively. There was also a difference between survival of patients with negative (n ¼ 8) and positive (n ¼ 29) TBARs increment (log-rank P value p0.005, Fig 3) . Similar difference was seen for patients with negative (n ¼ 9) and positive (n ¼ 28) SB incre-ments (log-rank P value p0.002, graphic data not shown) due to almost the same individual TBARs and SB results distribution.
Discussion
We found that chemotherapy composed of carboplatin, etoposide and vincristine increases the serum levels of end-products of lipid peroxidation in a majority of SCLC patients. This is compatible to previous reports on enhanced generation of lipid peroxidation products in response to cancer chemotherapy. 2, 11 However, we describe for the first time (to our knowledge) that changes of serum levels of TBARs and SB are related to treatment efficacy and patients survival. The highest rise in serum TBARs and SB concentrations after the 1st course introduction was seen in responders that received all 6 cycles of chemotherapy. On the contrary, the significant decrease in end products of lipid peroxidation was observed in non-responders with progressive disease occurring before the 2nd chemotherapy cycle and shortest survival. TBARs are low molecular weight compounds formed via decomposition of certain primary and secondary lipid peroxidation products. 17 MDA is one of the most important TBARs, however, it is formed not only during oxidative degradation of polyunsaturated fatty acids but is also generated as a side product of eicosanoid formation and oxidative damage to other non-lipid biomolecules such as proteins, carbohydrates and nucleic acids. MDA can react with primary amines to give few products including fluorescent MDA:amine adduct called conjugated SB. 17 Positive correlations between baseline SB and TBARs levels and between treatment-induced increments in serum TBARs and SB in SCLC patients are in accordance with these data. All anticancer drugs used in our study have been reported to generate free radicals and induce oxidative stress with subsequent formation of lipid peroxidation products. 11, [18] [19] [20] This clearly explains the rise in circulatory TBARs and SB after chemotherapy in the whole group of SCLC patients and also in responders subgroup. However, non-responders especially those with early progression revealed the 1st chemotherapy course-induced decrease in both measured variables. Look and Musch reported a marked chemotherapy-induced increase in plasma TBARs levels in 10 of 12 patients with different carcinomas (in the remaining 2 patients no decrease was noted) but they did not analyze association between plasma TBARs and response to the treatment. 2 On the other hand, cisplatin combination chemotherapy in patients with lung cancer (group also involved SCLC patients) caused the decrease in the whole blood ability to produce reactive oxygen species upon stimulation with phorbol esters. This was independent of treatment efficacy, however, was mainly related to the decrease in number of circulating polymorphonuclear leucocytes. 21 Contrary to this, Sangeetha and coworkers reported increased plasma TBARs concentration and superoxide anion and H 2 O 2 production by polymorphonuclear leukocytes following cancer chemotherapy. 11 Few hypotheses may by raised to explain chemotherapy-induced decrease in SB and TBARs in SCLC patients with early progressive disease. Perhaps, (A) chemotherapy may favour accelerated MDA conversion into SB resulting in circulatory TBARs decrease. However, simultaneous decline in serum SB levels argues against this explanation. (B) Non-responders could have increased antioxidant defence. This may be rather responsible for inhibition of treatment-induced rise in serum TBARs and SB but not for their decrease. In addition, higher baseline SB and TBARs levels in nonresponders than in responders suggest enhanced ROS formation and imbalance between oxidants and antioxidants in SCLC patients with early occurrence of progressive disease. (C) Chemotherapy may enhance MDA (and other TBARs) catabo-lism by aldehyde dehydrogenases in liver 17 with secondary decrease in circulatory SB. Observation that activity of aldehyde dehydrogenase can be associated with tumor resistance to carboplatin and other anticancer drugs 22, 23 supports this hypothesis. In addition, 6 of 9 patients with negative TBARs increments had metastases in liver at the study entry. (D) MDA may be decomposed by excess of oxidants. 24, 25 SCLC ED patients with early occurrence of progressive disease are likely to have enhanced systemic oxidative stress. Additional amounts of ROS generated by chemotherapy could decompose MDA and be responsible for decrease in measured circulatory TBARs and SB. Two last hypotheses seem most likely but their confirmation requires further studies.
ARTICLE IN PRESS
Each consecutive chemotherapy cycle caused the lower rise in circulatory TBARs and SB while baseline levels of lipid peroxidation products rose with treatment duration in responders subgroup. Although plasma iron levels did not alter in these patients, chemotherapy may induce appearance of plasma nontransferrin-bound iron a potential prooxidant and decrease the concentration of low molecular weight antioxidants. 26 On the other hand, activity of cellular antioxidant enzymes may increase secondarily to treatment-induced oxidative stress 27 and be responsible for lower TBARs and SB increments after consecutive chemotherapy courses.
Our results suggests that end-products of lipid peroxidation may inhibit tumour growth in vivo. This is consistent with the observation that antitumour effect of degradable starch microspheres was dependent on TBARs generation in carcinoma tissues in rabbits. 28 Essential fatty acids and products of their metabolism are cytotoxic and alter drug resistance of tumour cell cultures. 29 In addition, MDA at concentration 1 mM induced the cell cycle arrest of the lung cancer-derived cell line in vitro. 6 Although serum TBARs levels were many times lower in SCLC patients it is possible that TBARs concentrations in the close neighbourhood of tumour may reach values similar to that used in experiments in vitro. Low catalase activity 30 and increased hydrogen peroxide release from lung cancer tissue 4 may predispose to enhanced generation of lipid peroxidation products after chemotherapy.
The ratio of LD to ED patients was similar in SCLC responder and non-responder subgroups. However, this was quite different in SCLC non-responders with late progression and non-responders with early progression subgroup (8/1 vs. 1/8). Non-responders with early progression revealed a decrease in circulatory TBARs and SB after introduction of chemotherapy. It suggests that occurrence of ED at the study entry predisposes to decrease in endproducts of lipid peroxidation in response to chemotherapy. This may consist in increased baseline ROS production and/or increased activity of enzymes decomposing MDA and other TBARs.
No significant association between survival and TBARs and SB changes was found in the SCLC responders subgroup that revealed increase in endproducts of lipid peroxidation. Perhaps, the decrease in circulatory TBARs and SB has higher significance and is important for early occurrence of progressive disease and survival shortening. The coexistence of treatment-induced TBARs and SB decrease with other processes promoting tumour growth cannot be excluded, however, it requires further studies. In conclusion, we found that simple monitoring of treatment (carboplatin, etoposide, vincristine)-induced changes of end-products of lipid peroxidation may by helpful for screening of SCLC patients with high risk of early disease progression and chemotherapy failure.
